Antelope Dx raises 5.1 million euros

ntelope Dx is developing a point-of-need diagnostic platform that allows patients to gain access to relevant health parameters on site.

A consortium of investors, including RMM (Rudi Marien), and Saffelberg (Jos Sluys), has invested in the new spin-off Antelope Dx. Together with a number of business angels, they have invested 5.1 million euros in the development of innovative point-of-need technology and applications.

The Antelope technology is the result of 10 years of research at the photonics research group of Ghent University. MyCartis has further developed the technology since the middle of last year. MyCartis now places this business unit in Antelope Dx, which is established as a spin-off from UGent and MyCartis.

Fast and accurate home test Antelope Dx is developing a point-of-need diagnostic platform that allows patients, consumers and health care professionals to access relevant health parameters on site. The Antelope technology aims to achieve the performance of a test in clinical laboratories with the ease of use of a pregnancy test, at a price that remains affordable for the consumer. The platform has been developed on the basis of innovative “lab-on-chip” technology that allows rapid and accurate testing to be carried out on any (liquid) steel without steel preparation or complex operations.

The first test in development is a home test that can detect two of the most common STDs (Sexually Transmitted Diseases), Chlamydia trachomatis (CT) and Neisseria gonorrhea (NG), in urine. The second test aims to detect the presence of bacterial markers in a blood sample in patients with signs of infection, thereby supporting doctors and other health care professionals in administering antibiotics or not.

Antelope Dx is located in the BIOSCAPE incubator in Ghent-Zwijnaarde and employs about 15 people.

  • (in development)